当前位置: 首页 >> 检索结果
共有 18965 条符合本次的查询结果, 用时 4.5716136 秒

161. Endoscopic papillectomy versus surgical ampullectomy for adenomas and early cancers of the papilla: a retrospective Pancreas2000/European Pancreatic Club analysis.

作者: Marcus Hollenbach.;Christian Heise.;Einas Abou-Ali.;Aiste Gulla.;Francesco Auriemma.;Kevin Soares.;Galen Leung.;Mark A Schattner.;William R Jarnagin.;Tiegong Wang.;Fabrice Caillol.;Marc Giovannini.;Yanis Dahel.;Thilo Hackert.;Woo Hyun Paik.;Alessandro Zerbi.;Gennaro Nappo.;Bertrand Napoleon.;Urban Arnelo.;Erik Haraldsson.;Asif Halimi.;Alexander Waldthaler.;Uwe Will.;Rita Saadeh.;Viliam Masaryk.;Sophia E van der Wiel.;Marco J Bruno.;Enrique Perez-Cuadrado-Robles.;Pierre Deprez.;Alain Sauvanet.;Louisa Bolm.;Tobias Keck.;Régis Souche.;Jean-Michel Fabre.;Nicolas Musquer.;Georg Kähler.;Steffen Seyfried.;Maria Chiara Petrone.;Alberto Mariani.;Piera Zaccari.;Giulio Belfiori.;Stefano Crippa.;Massimo Falconi.;Stefano Partelli.;Bengisu Yilmaz.;Ihsan Ekin Demir.;Güralp O Ceyhan.;Sohei Satoi.;Jean Marc Regimbeau.;Johan Gagniére.;Alessandro Repici.;Andrea Anderloni.;Charles Vollmer.;Fabio Casciani.;Marco Del Chiaro.;Atsushi Oba.;Richard D Schulick.;Arthur Berger.;Laura Maggino.;Roberto Salvia.;Peter Schemmer.;Doerte Wichmann.;Yosuke Inoue.;Mario Dinis-Ribeiro.;Ana Laranjo.;Diogo Libanio.;Tobias Kleemann.;Vasile Sandru.;Madaline Ilie.;Reea Ahola.;Johanna Laukkarinen.;Brigitte Schumacher.;David Albers.;Tiago Cúrdia Gonçalves.;Louise Barbier.;Ephrem Salamé.;Tobias J Weismüller.;Dominik Heling.;Arnaud Alves.;Elias Karam.;Nicolas Regenet.;Ana Dugic.;Steffen Muehldorfer.;Stéphanie Truant.;Karel Caca.;Benjamin Meier.;Bogdan P Miutescu.;Marcel Tantau.;David Birnbaum.;Rainer Christoph Miksch.;Edris Wedi.;Katrin Salzmann.;Matthieu Bruzzi.;Renato M Lupinacci.;Patrice David.;Charles De Ponthaud.;Arthur Schmidt.;Sara Regnér.;Sebastien Gaujoux.; .
来源: Gut. 2025年74卷3期397-409页
Ampullary neoplastic lesions can be resected by endoscopic papillectomy (EP) or transduodenal surgical ampullectomy (TSA) while pancreaticoduodenectomy is reserved for more advanced lesions. We present the largest retrospective comparative study analysing EP and TSA.

162. Time for arginine methylation: PRMT5 inhibition to advance cholangiocarcinoma treatment.

作者: Romain Désert.;Lipika Goyal.;Thomas F Baumert.
来源: Gut. 2025年74卷6期878-880页

163. Response letter to the editor.

作者: Jana Jarošová.;Tomas Hucl.
来源: Gut. 2025年74卷3期501页

164. Primary prophylaxis in patients with high risk oesophageal varices to prevent oesophageal variceal bleeding (OVB)-The CAVARLY is stronger together!!

作者: Harsh Vardhan Tevethia.;Apurva Pande.;Rajan Vijayaraghavan.;Guresh Kumar.;Shiv Kumar Sarin.
来源: Gut. 2025年74卷5期870-871页

165. Genetic variation at 11q23.1 confers colorectal cancer risk by dysregulation of colonic tuft cell transcriptional activator POU2AF2.

作者: Vidya Rajasekaran.;Bradley T Harris.;Ruby T Osborn.;Claire Smillie.;Kevin Donnelly.;Marion Bacou.;Edward Esiri-Bloom.;Li-Yin Ooi.;Morven Allan.;Marion Walker.;Stuart Reid.;Alison Meynert.;Graeme Grimes.;James P Blackmur.;Peter G Vaughan-Shaw.;Philip J Law.;Ceres Fernández-Rozadilla.;Ian Tomlinson.;Richard S Houlston.;Kevin B Myant.;Farhat Vn Din.;Maria Timofeeva.;Malcolm G Dunlop.;Susan M Farrington.
来源: Gut. 2025年74卷5期787-803页
Common genetic variation at 11q23.1 is associated with colorectal cancer (CRC) risk, exerting local expression quantitative trait locus (cis-eQTL) effects on POU2AF2, COLCA1 and POU2AF3 genes. However, complex linkage disequilibrium and correlated expression has hindered elucidation of the mechanisms by which genetic variants impart underlying CRC risk.

166. Recent advances in incretin-based therapy for MASLD: from single to dual or triple incretin receptor agonists.

作者: Giovanni Targher.;Alessandro Mantovani.;Christopher D Byrne.;Herbert Tilg.
来源: Gut. 2025年74卷3期487-497页
Clinically effective pharmacological treatment(s) for metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form metabolic dysfunction-associated steatohepatitis (MASH) represent a largely unmet need in medicine. Since glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been licensed for the treatment of type 2 diabetes mellitus and obesity, they were one of the first drug classes to be examined in individuals with MASLD/MASH. Successful phase 2 randomised clinical trials with these agents have resulted in progression to phase 3 clinical trials (principally testing the long-term efficacy of subcutaneous semaglutide). Over the last few years, in addition to GLP-1RAs, newer agents with glucose-dependent insulinotropic peptide and/or glucagon receptor agonist functions have been tested, with increasing evidence from phase 2 randomised clinical trials of histological improvements in MASLD/MASH, as well as benefits on MASLD-related extrahepatic complications. Based on this background of evidence, single, dual or triple incretin receptor agonists are becoming an attractive and promising treatment option for MASLD or MASH, particularly in individuals with coexisting obesity or type 2 diabetes mellitus. In this narrative review, we examine the rapidly expanding body of clinical evidence supporting a role of incretin-based pharmacotherapies in delaying or reversing MASH progression. We also discuss the biology of incretins and the putative hepatoprotective mechanisms of incretin-based pharmacotherapies for managing MASLD or MASH.

167. Sphincterotomy with FCSEMS (SPHINX): a monumental answer or the beginning of new mysteries?

作者: Mohan Ramchandani.;Aniruddha Pratap Singh.;Rupjyoti Talukdar.;D Nageshwar Reddy.
来源: Gut. 2025年74卷6期1024页

168. Top-down infliximab plus azathioprine versus azathioprine alone in patients with acute severe ulcerative colitis responsive to intravenous steroids: a parallel, open-label randomised controlled trial, the ACTIVE trial.

作者: Aurelien Amiot.;Philippe Seksik.;Antoine Meyer.;Carmen Stefanescu.;Pauline Wils.;Romain Altwegg.;Lucine Vuitton.;Laurianne Plastaras.;Adrien Nicolau.;Bruno Pereira.;Nicoals Duveau.;David Laharie.;Bassirou Mboup.;Medina Boualit.;Matthieu Allez.;Sylvie Rajca.;Elise Chanteloup.;Guillaume Bouguen.;Thomas Bazin.;Felix Goutorbe.;Nicolas Richard.;Driffa Moussata.;Eric Vicaut.;Laurent Peyrin-Biroulet.
来源: Gut. 2025年74卷2期197-205页
It is unknown which maintenance therapy is the most effective option for patients admitted for an acute severe ulcerative colitis (ASUC) episode responding to intravenous steroids.

169. Spatial dissection of tumour microenvironments in gastric cancers reveals the immunosuppressive crosstalk between CCL2+ fibroblasts and STAT3-activated macrophages.

作者: Sung Hak Lee.;Dagyeong Lee.;Junyong Choi.;Hye Jeong Oh.;In-Hye Ham.;Daeun Ryu.;Seo-Yeong Lee.;Dong-Jin Han.;Sunmin Kim.;Youngbeen Moon.;In-Hye Song.;Kyo Young Song.;Hyeseong Lee.;Seungho Lee.;Hoon Hur.;Tae-Min Kim.
来源: Gut. 2025年74卷5期714-727页
A spatially resolved, niche-level analysis of tumour microenvironments (TME) can provide insights into cellular interactions and their functional impacts in gastric cancers (GC).

170. Divergent lineage trajectories and genetic landscapes in human gastric intestinal metaplasia organoids associated with early neoplastic progression.

作者: Sarah S K Yue.;Yin Tong.;Hoi Cheong Siu.;Siu Lun Ho.;Simon Y K Law.;Wai Yin Tsui.;Dessy Chan.;Yuanhua Huang.;Annie S Y Chan.;Shui Wa Yun.;Ho Sang Hui.;Jee-Eun Choi.;Matthew S S Hsu.;Frank P L Lai.;April S Chan.;Siu Tsan Yuen.;Hans Clevers.;Suet Yi Leung.;Helen H N Yan.
来源: Gut. 2025年74卷4期522-538页
Gastric intestinal metaplasia (IM) is a precancerous stage spanning a morphological spectrum that is poorly represented by human cell line models.

171. Faecal phageome transplantation alleviates intermittent intestinal inflammation in IBD and the timing of transplantation matters: a preclinical proof-of-concept study in mice.

作者: Nengneng Li.;Yue Li.;Ziyu Huang.;Zhirui Cao.;Cha Cao.;Xiang Gao.;Tao Zuo.
来源: Gut. 2025年74卷5期868-870页

172. Identifying colorectal cancer-specific vulnerabilities in the Wnt-driven long non-coding transcriptome.

作者: Laura J Schwarzmueller.;Ronja S Adam.;Leandro F Moreno.;Lisanne E Nijman.;Adrian Logiantara.;Steven Eleonora.;Oscar Bril.;Sophie Vromans.;Nina E de Groot.;Francesca Paola Giugliano.;Ekaterina Stepanova.;Vanesa Muncan.;Clara C Elbers.;Kristiaan J Lenos.;Danny A Zwijnenburg.;Monique A J van Eijndhoven.;Dirk Michiel Pegtel.;Sanne M van Neerven.;Fabricio Loayza-Puch.;Tulin Dadali.;Wendy J Broom.;Martin A Maier.;Jan Koster.;Louis Vermeulen.;Nicolas Léveillé.
来源: Gut. 2025年74卷4期571-585页
Aberrant Wnt pathway activation is a key driver of colorectal cancer (CRC) and is essential to sustain tumour growth and progression. Although the downstream protein-coding target genes of the Wnt cascade are well known, the long non-coding transcriptome has not yet been fully resolved.

173. Liquid biopsy to identify Barrett's oesophagus, dysplasia and oesophageal adenocarcinoma: the EMERALD multicentre study.

作者: Jinsei Miyoshi.;Alessandro Mannucci.;Marco Scarpa.;Feng Gao.;Shusuke Toden.;Timothy Whitsett.;Landon J Inge.;Ross M Bremner.;Tetsuji Takayama.;Yulan Cheng.;Teodoro Bottiglieri.;Iris D Nagtegaal.;Martha J Shrubsole.;Ali H Zaidi.;Xin Wang.;Helen G Coleman.;Lesley A Anderson.;Stephen J Meltzer.;Ajay Goel.; .
来源: Gut. 2025年74卷2期169-181页
There is no clinically relevant serological marker for the early detection of oesophageal adenocarcinoma (EAC) and its precursor lesion, Barrett's oesophagus (BE).

174. Devices substitution can reduce environmental burden: what about strategies substitution?

作者: Raphaëlle Grau.;Jérémie Jacques.;Jérôme Rivory.;Mathieu Pioche.
来源: Gut. 2025年74卷5期872-874页

175. CAF-macrophage crosstalk in tumour microenvironments governs the response to immune checkpoint blockade in gastric cancer peritoneal metastases.

作者: Yuanfang Li.;Yongqiang Zheng.;Jiaqian Huang.;Run-Cong Nie.;Qi-Nian Wu.;Zhijun Zuo.;Shuqiang Yuan.;Kai Yu.;Cheng-Cai Liang.;Yi-Qian Pan.;Bai-Wei Zhao.;Yuhong Xu.;Qihua Zhang.;Yashang Zheng.;Junquan Chen.;Zhao-Lei Zeng.;Wei Wei.;Ze-Xian Liu.;Rui-Hua Xu.;Hui-Yan Luo.
来源: Gut. 2025年74卷3期350-363页
Peritoneal metastasis is the most common metastasis pattern of gastric cancer. Patients with gastric cancer peritoneal metastasis (GCPM) have a poor prognosis and respond poorly to conventional treatments. Recently, immune checkpoint blockade (ICB) has demonstrated favourable efficacy in the treatment of GCPM. Stratification of best responders and elucidation of resistance mechanisms of ICB therapies are highly important and remain major clinical challenges.

176. Recent advances in clinical practice: mastering the challenge-managing IBS symptoms in IBD.

作者: Judith Wellens.;João Sabino.;Tim Vanuytsel.;Jan Tack.;Séverine Vermeire.
来源: Gut. 2025年74卷2期312-321页
Many patients with IBD report persisting symptoms, despite resolution of the inflammatory process. Although by definition, a diagnosis of IBS cannot be made, the prevalence of 'IBS in IBD' surpasses the rate of IBS in the global population by fivefold. Because IBS-like symptoms are associated with a decreased quality of life and increased healthcare utilisation in IBD, diagnosis and treatment are necessary. In this review, we summarise the current knowledge on IBS-like symptoms in IBD. A pathophysiological common ground is present, which includes genetic susceptibility, environmental triggers, gut microbial dysbiosis, increased intestinal permeability, visceral hypersensitivity and involvement of brain-gut interaction. When symptoms persist after resolution of inflammation, other GI diseases should be excluded based on the chief complaint, considering any possible psychological co-morbidity early in the diagnostic work-up. Subsequent treatment should be initiated that is evidence-based and often multimodal, including classical and non-classical pharmacological agents as well as lifestyle and microbiota-based approaches, spanning the breadth of the gut, brain and its interaction. Treatment goals in this substantial part of the IBD population should be adapted to not only focus on treating the inflammation but taking care of the patient.

177. Large proximal gastric GIST tumours: downsizing by imatinib and subsequent endoresection.

作者: Ayimukedisi Yalikong.;Baohui Song.;Dongli He.;Enpan Xu.;Zhipeng Qi.;Yunshi Zhong.
来源: Gut. 2025年74卷3期346-349页

178. Correction: The road to a world-unified approach to the management of patients with gastric intestinal metaplasia: a review of current guidelines.

来源: Gut. 2024年73卷12期e1页

179. Endoscopic stratification of gastric intestinal metaplasia: where are we, where do we want to go and how do we get there?

作者: Shailja C Shah.;Mario Dinis-Ribeiro.
来源: Gut. 2025年74卷5期867-868页

180. Quest for HBV functional cure: what have we learnt from silencing RNAs?

作者: Norah Terrault.;Anna S Lok.
来源: Gut. 2025年74卷3期340-342页
共有 18965 条符合本次的查询结果, 用时 4.5716136 秒